horizon

All Post Office Horizon victims entitled to free legal advice for first time

Emma SimpsonBusiness correspondent and

Emer MoreauBusiness reporter

PA Media Campaigners outside Aldwych House, central London, where the Post Office Horizon IT inquiry is taking place - they are holding up two banners, a blue one with the text Justice for subpostmasters alliance - and a second red one with SOS: Support our Sub-postmasters written on it PA Media

All victims of the Post Office Horizon IT scandal who are claiming compensation will now be entitled to free legal advice to help them with their offers, the government has announced.

The change could potentially have a major effect on the size of the payouts some victims are able to achieve.

It is one of a number of improvements to the compensation schemes available to victims, made in response to the first report from the public inquiry into the scandal, widely described as one of the UK’s worst ever miscarriages of justice.

In July, the chair of the inquiry, Sir Wyn Williams, delivered his findings into the human impact of the scandal and called for urgent action.

The government said it has accepted all but one of the recommendations relating specifically to Horizon.

More than 900 sub-postmasters were prosecuted after the faulty Horizon computer system made it look like money was missing from their branch accounts.

Hundreds of others poured their own savings into their branch to make up apparent shortfalls in order to avoid prosecution.

Making the announcement, Business Secretary Peter Kyle said there was “clearly more to do to bring justice to those affected” and accepting the recommendations was a “crucial step” towards doing this.

There are now three compensation schemes for victims in various circumstances, but they have been criticised for being too slow and complicated with many of the worst affected victims receiving offers for far less than they’d originally claimed for.

Victims who have sought compensation through the Horizon Shortfall Scheme (HSS) – which accounts for more than half of the compensation claims paid out so far – are now eligible for government-funded legal advice to help them decide whether to accept a fixed sum offer, in changes announced by the government on Thursday.

This brings it in line with the other schemes.

The government has also committed to setting up a new appeals process for postmasters who accepted a fixed payout under the HSS scheme, which also includes funded legal advice.

Many victims have previously complained about being forced to accept low offers of compensation, without the benefit of legal help.

Action taken in response to other recommendations included:

  • the government extending the date for the closure of the HSS scheme
  • giving greater clarity on the definition of “full and fair redress”
  • starting work on a restorative justice project for postmasters

So far, more than £1.2bn has been paid out to more than 9,000 claimants across all of the compensation schemes.

The Post Office said it had been working closely with the Government to respond to the inquiry’s report and had agreed a deadline of the end of January 2026 for accepting new applications to the Horizon Shortfall Scheme, saying it would give potential applicants more time to consider their case.

“I encourage any current or former postmaster who thinks they might be eligible for the Horizon Shortfall Scheme to get in touch ahead of the closure date. We have a dedicated claimant support team available on the phone to discuss your options, provide support, and answer any questions so we can begin to process your claim right away,” said Post Office Chair, Nigel Railton.

Reacting, a spokesperson for Fujitsu – who provided the Horizon IT system – said the company had “apologised for, and deeply regret, our role in sub-postmasters’ suffering”.

‘Battling all the time’

Tony Downey Tony Downey, a white man, wearing a black and blue rain coat over a grey t shirt.Tony Downey

Tony Downey and his wife Caroline were victims of the Post Office scandal

Tony Downey bought the Hawkshead Post Office in the Lake District in 2001.

He and his wife Caroline were forced to put in £35,000 of their own savings to make up for “losses” created by the faulty software.

He lost his home, his livelihood and went bankrupt as a result. His health has also suffered.

Mr Downey is still waiting for full compensation nearly three years after submitting his claim.

“It just seems to be battling, all the time, to get a little bit more, and a little bit more, and a little bit more,” he said. “We’re just exhausted with it.”

Responding to Mr Downey’s testimony, a government spokesperson said: “While we do not comment on individual cases, we take every effort to make full and fair offers to all claimants and only request information that will enable us to do so.”

Neil Hudgell of Hudgell Solicitors, which represents hundreds of victims, said it is “proper that applicants are entitled to have their cases fully assessed before electing to accept a fixed sum”.

He said there would likely be “an upturn in numbers” seeking compensation as deadlines for applying are set.

“There are clearly going to be a lot more claims in the system,” he said.

Mr Hudgell added that claims were still being processed slowly, and said that unless more resources were invested to speed up claims handling, “we will still be needing to talk about compensation claims in three to five years’ time.”

Source link

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon

There is a “for sale” sign on the sector, and these two stocks look particularly attractive at their current levels.

According to some research, healthcare stocks are about as cheap as they have been in three decades. Many have experienced significant headwinds recently, but for opportunistic investors, now may be a great time to explore the industry for potential deals. Plenty of promising, yet beaten-down, healthcare stocks can be had at reasonable valuations relative to their growth potential.

Two that are worth serious consideration are Pfizer (PFE -0.50%) and Vertex Pharmaceuticals (VRTX -1.00%). Here’s more on these drugmakers.

Patient shopping for medicine in a pharmacy.

Image source: Getty Images.

1. Pfizer

Pfizer is staring down the barrel of several patent cliffs that should happen by the end of the decade. For example, the company’s anticoagulant, Eliquis, will lose patent exclusivity by 2029 at the latest. The market is factoring that in, and in addition to the poor financial results Pfizer has produced lately, it explains its terrible performance on the market over the past few years.

However, Pfizer is rebounding. In the second quarter, Pfizer’s revenue increased by 10% year over year to $14.7 billion. The company’s adjusted earnings per share grew 30% year over year to $0.78. These are strong results for a pharmaceutical giant.

Furthermore, Pfizer’s pipeline should enable it to overcome the upcoming loss of patent exclusivity. The company has earned approval for several new products in recent years that are still in their early growth stages, especially considering that some of them are expected to receive label expansions. Abrysvo, a vaccine for the respiratory syncytial virus, is one such newer product whose second-quarter revenue increased by 155% year over year to $143 million.

Elsewhere, Pfizer has significantly improved its pipeline in recent years through licensing deals in acquisitions. The company’s oncology pipeline appears particularly promising, boasting dozens of programs, at least some of which should yield excellent clinical results in the coming years.

Lastly, Pfizer has been engaged in cost-cutting efforts. The company is on track to deliver net cost savings of $4.5 billion by the end of the year and $7.2 billion by the end of 2027. These initiatives should help boost Pfizer’s bottom line, and they are even more important considering President Trump’s aggressive tariffs.

Pfizer’s overall business still looks robust enough to recover, despite upcoming headwinds. The stock’s forward price-to-earnings (P/E) ratio of 7.7 appears dirt cheap when compared to the industry average of 16.5 for the healthcare sector. The stock is a great choice for value investors right now.

2. Vertex Pharmaceuticals

Vertex Pharmaceuticals’ forward P/E tops 20, which makes the stock look fairly expensive compared to its healthcare peers. And when we consider that the company has encountered setbacks this year, including clinical trial failures and the distribution of some illegal knockoffs of its medicines in Russia, which has impacted its sales, the picture looks even bleaker.

But at current levels, Vertex Pharmaceuticals looks attractive considering its potential. For one, the company still holds a monopoly in cystic fibrosis (CF), a rare lung disease. And in that niche, Vertex Pharmaceuticals has a reasonable amount of whitespace. Although its first CF medicine has been on the market for over a decade, Vertex has developed newer and better products.

Trikafta and Alyftrek, Vertex’s newest launches in CF, won’t lose patent exclusivity until the late 2030s. In the meantime, thousands of patients eligible for these medicines remain untreated. Translation: Expect reasonable revenue growth from this franchise for the foreseeable future.

Now add to that the company’s newer launches: Journavx in acute pain and Casgevy in beta-thalassemia and sickle cell disease. The former fills a need: It became the first approved oral, non-opioid pain inhibitor. Opioid-based therapies come with the risk of addiction and other potentially severe adverse reactions. Journavx was only approved in January. It should make a meaningful impact on Vertex’s results sooner rather than later.

Casgevy’s case is a bit different. It first earned regulatory approval in late 2023, but it has not yet contributed significantly to Vertex’s sales. That’s because it is an expensive gene editing therapy that is complex to administer. However, Vertex Pharmaceuticals is making progress in securing deals with third-party payers. Casgevy has little competition and should also, eventually, see its sales ramp up.

Beyond that, Vertex Pharmaceuticals could earn approval for zimislecel, a therapy for type 1 diabetes, within two years. The company also has late-stage candidates that could make significant progress in the meantime. Vertex still has significant upside from its current levels. The stock has faced headwinds this year, but a turnaround is, indeed, on the horizon for the biotech stock.

Source link